Panacea Biotec Limited (BOM:531349)

Panacea Biotec Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	643.7	821.25	471.74	398.52	503.5
Short-Term Investments	-	100.3	440.91	638.99	1,598	4,963
Trading Asset Securities	-	-	31.53	403.62	134.16	50.01
Cash & Short-Term Investments	744	744	1,294	1,514	2,130	5,516
Cash Growth	-32.44%	-42.49%	-14.57%	-28.92%	-61.38%	505.00%
Accounts Receivable	-	735.2	725.57	574.19	600.92	816.56
Other Receivables	-	-	11.58	10.57	12.02	10.58
Receivables	-	754.6	762.82	618.08	628.74	841.54
Inventory	-	1,928	2,137	1,779	2,021	2,127
Prepaid Expenses	-	-	71.08	60.63	52.2	53.49
Other Current Assets	-	1,704	1,187	882.26	850.84	1,367
Total Current Assets	-	5,130	5,452	4,855	5,683	9,906
Property, Plant & Equipment	-	6,532	6,369	6,348	6,163	6,255
Long-Term Investments	-	0.7	1.17	1.72	1.74	803.91
Other Intangible Assets	-	508.9	360.91	276.32	153.3	132.36
Long-Term Deferred Tax Assets	-	-	-	-	-	237.51
Long-Term Deferred Charges	-	-	61.71	83.66	106.11	5.88
Other Long-Term Assets	-	449.3	652.84	843.43	600.99	248.48
Total Assets	-	12,622	12,897	12,408	12,712	17,589

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	1,896	2,258	1,456	1,773	2,347
Accrued Expenses	-	394.8	369.66	439.6	361.43	404.63
Short-Term Debt	-	-	-	-	0.55	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.52
Current Income Taxes Payable	-	20.3	0.08	1.35	5.6	0.85
Current Unearned Revenue	-	-	17.69	171.03	196.62	-
Other Current Liabilities	-	1,176	1,025	1,022	980.88	5,010
Total Current Liabilities	-	3,487	3,670	3,090	3,318	7,764
Long-Term Debt	-	236.6	222.06	209.94	201.64	341.03
Long-Term Unearned Revenue	-	-	108.52	218.46	321.39	455.88
Pension & Post-Retirement Benefits	-	-	191.06	164.51	134.25	144.26
Long-Term Deferred Tax Liabilities	-	231.4	232.82	225.45	203.71	-
Other Long-Term Liabilities	-	378.1	166.91	117.78	131.22	147.3
Total Liabilities	-	4,333	4,591	4,026	4,311	8,852

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	61.3	61.25	61.25	61.25	61.25
Additional Paid-In Capital	-	-	919.4	919.4	919.4	919.4
Retained Earnings	-	-	8,594	8,678	8,694	9,041
Comprehensive Income & Other	-	8,287	-1,443	-1,455	-1,455	-1,472
Total Common Equity	8,348	8,348	8,131	8,204	8,219	8,550
Minority Interest	-	-59.6	-41.7	-38.21	-34.89	-29.81
Shareholders' Equity	8,289	8,289	8,306	8,382	8,401	8,737
Total Liabilities & Equity	-	12,622	12,897	12,408	12,712	17,589

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	236.6	236.6	222.06	209.94	202.19	341.55
Net Cash (Debt)	507.4	507.4	1,072	1,304	1,928	5,175
Net Cash Growth	-42.28%	-52.65%	-17.85%	-32.35%	-62.74%	-
Net Cash Per Share	8.34	8.31	17.50	21.30	31.48	84.48
Filing Date Shares Outstanding	60.53	65	61.25	61.25	61.25	61.25
Total Common Shares Outstanding	60.53	65	61.25	61.25	61.25	61.25
Working Capital	-	1,644	1,782	1,765	2,365	2,142
Book Value Per Share	128.44	128.44	132.75	133.94	134.19	139.59
Tangible Book Value	7,840	7,840	7,770	7,928	8,066	8,417
Tangible Book Value Per Share	120.61	120.61	126.86	129.43	131.69	137.43
Land	-	-	2,068	2,059	2,059	2,027
Buildings	-	-	3,155	3,196	3,333	3,333
Machinery	-	-	6,624	6,442	6,509	6,512
Construction In Progress	-	-	935.13	747.15	280.07	49.12

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error